BMY Stock UPDATES Bristol-Myers Squibb Company (BMY) 58.19 11/02/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 2, 2014 at 8:53 PM

Bristol-Myers Squibb Company (BMY) 58.19 $BMY

Final Glance: Pharmaceuticals companies
AP - Fri Oct 31, 5:04PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)

Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 92.18 (-0.65), AGN: 190.06 (+0.62), ACT: 242.74 (-0.47), BMY: 58.19 (-0.79)

Midday Glance: Pharmaceuticals companies
AP - Fri Oct 31, 1:49PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)

Early Glance: Pharmaceuticals companies
AP - Fri Oct 31, 11:28AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 107.78 (+0.74), BAX: 70.14 (+0.08), PFE: 29.95 (+0.11), BMY: 58.19 (-0.79)

Cramer on the Stock Market: Find the Best of Best-of-Breed Stocks
at The Street - Fri Oct 31, 9:54AM CDT
Remember these franchises and who captains them.
AGN: 190.06 (+0.62), MMM: 153.77 (+1.67), CMG: 638.00 (-1.68), BMY: 58.19 (-0.79)

AbbVie Q3 Earnings Top on Humira Sales, Boosts Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 9:33AM CDT
AbbVie (ABBV) raised it outlook for 2014 - the new guidance surpassed expectations.
AGN: 190.06 (+0.62), SHPG: 199.80 (+0.38), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79)

Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:39AM CDT
Bristol-Myers Squibb Company (BMY) was a big mover last session, as its shares rose nearly 9% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), ILMN: 192.58 (-0.84), BMY: 58.19 (-0.79)

Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong
at The Street - Thu Oct 30, 7:11PM CDT
The end of quantitative easing was supposed to create a laundry list of problems, Cramer says. It didn't happen.
MMM: 153.77 (+1.67), BIIB: 321.08 (+0.08), HON: 96.12 (+0.53), FB: 74.99 (+0.88), BMY: 58.19 (-0.79), MGM: 23.25 (+0.27), ATK: 116.96 (+6.77), YRCW: 21.44 (+3.24), UPS: 104.91 (+1.62), SLB: 98.66 (+1.04), CELG: 107.09 (+0.15), WPRT: 6.17 (+0.12), SBUX: 75.56 (-1.76), TTWO: 26.45 (+1.18), DO: 37.71 (-0.94), ETP: 64.43 (+0.41), GILD: 112.00 (-2.22), ARR: 3.96 (-0.01), CMG: 638.00 (-1.68), MPEL: 27.14 (+0.78), WNC: 10.30 (+0.81), CRL: 63.16 (+0.35), AAPL: 108.00 (+1.02), REGN: 393.72 (+0.92)

Lung cancer drug promising
at Investor's Business Daily - Thu Oct 30, 6:14PM CDT
Bristol-Myers Squibb (BMY) reported good midstage trial results for its drug candidate Opdivo in advanced squamous-cell lung cancer, boosting its share price. The drugmaker said that a year after the treatment, 41% of patients were still alive;...
BMY: 58.19 (-0.79)

Eli Lilly/Boehringer Ingelheim Restructure Diabetes Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:05PM CDT
Eli Lilly (LLY) and partner Boehringer Ingelheim amended the operational and financial structure of their diabetes collaboration in certain countries.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)

Most active New York Stock Exchange-traded stocks
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KO: 41.88 (+0.48), AVP: 10.40 (+0.43), F: 14.09 (+0.14), GE: 25.81 (+0.14), ABX.TO: 13.38 (-0.37), ABX: 11.87 (-0.42), PFE: 29.95 (+0.11), BAC: 17.16 (+0.13), BMY: 58.19 (-0.79), RAD: 5.25 (+0.07), AA: 16.76 (+0.54), YRI.TO: 4.49 (-0.50), S: 5.93 (-0.07), TWTR: 41.47 (-0.33), AUY: 3.98 (-0.48)

Bristol-Myers Squibb (BMY) Stock Is Gaining on Positive Phase 2 Results
at The Street - Thu Oct 30, 1:30PM CDT
Bristol-Myers Squibb (BMY) shares are climbing after its lung cancer treatment showed positive phase 2 test results.
BMY: 58.19 (-0.79)

Big Pharma Solid Q3 Earnings Put These ETFs in Focus - ETF News And Commentary
Sweta Killa - ZACKS - Thu Oct 30, 1:00PM CDT
Pharma ETFs have been surging over the past one week buoyed by solid earnings from big industry players.
IHE: 145.99 (-0.68), JNJ: 107.78 (+0.74), PPH: 63.38 (+0.22), PJP: 68.69 (+0.02), MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)

Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement
Business Wire - Thu Oct 30, 12:00PM CDT
Bristol-Myers Squibb Company (NYSE:BMY) and Lonza today announced a multi-year expansion of their existing biologics manufacturing agreement. The contract expansion will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza's mammalian manufacturing facility in Portsmouth, New Hampshire. Financial terms were not disclosed.
BMY: 58.19 (-0.79)

Bristol-Myers Squibb/Otsuka's Abilify is a Preferred Branded Agent for the Treatment of Schizophrenia, According to Surveyed U.S. Psychiatrists and Payers
PR Newswire - Thu Oct 30, 11:45AM CDT
Decision Resources Group finds that Bristol-Myers Squibb/Otsuka's Abilify is the branded agent with the highest patient share in schizophrenia, according to U.S. psychiatrists surveyed. Abilify is also one of the most preferred branded antipsychotics relative to other branded antipsychotics, according to surveyed managed care organization (MCO) medical director/pharmacy directors (MDs/PDs). The findings also reveal that the majority of surveyed psychiatrists perceive current antipsychotics to be only somewhat effective in reducing negative or cognitive symptoms of schizophrenia. Among emerging agents that were profiled, encenicline (Forum Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma) garnered the greatest expected patient share from surveyed psychiatrists, if the drug were to be reimbursed on a favorable tier for the treatment of cognitive impairment associated with schizophrenia (CIAS).
BMY: 58.19 (-0.79)

Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79), CRL: 63.16 (+0.35)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Terrabis Revolutionizes Illinois with Dual-Window Dispensary

Terrabis Unveils a Speedier Cannabis Experience What do you do when the world is demanding faster service? You innovate. That’s precisely what Terrabis has done by unveiling Illinois' first dual-window drive-thru dispensary in Grayville. Situated just off I-64, this facility isn't just offering a new way of doing things; it's setting the stage for what might very well...

Charity's Bold Move: Acquiring Wayfinder for K-12 Impact

Public Charity Expands Into Education Well, here's something that's bound to turn a few heads: a fast-growing public charity has just made its first acquisition in the K-12 sphere by snapping up Wayfinder. The stakes are getting interesting. When a charity starts playing in the acquisition space, you're looking at a change in strategy that deserves close attention. Why...

AI Data Retention: FastGPT’s Detailed Deletion Protocols

In the world of AI-driven applications, data retention has become a hot potato, especially when we're talking about sensitive information like conversation records and audit logs. FastGPT, an open-source AI platform, has decided to tell it like it is by detailing exactly how these data pieces are retained and ultimately booted out. All this info was scattered to the winds...

Curaleaf Expands in Florida Amid Rising Cannabis Demand

Curaleaf's Bold Moves in Florida's Ganja Gold Rush Fresh out of the gate, Curaleaf is saddling up for a wild ride into Florida's cannabis frontier. They've just thrown open the doors of their latest dispensary in Riverview, cranking their statewide count up to 77. Now, isn’t that something? If you're tracking these folks, you know that bringing their nationwide total to...

TECNO Unleashes New Laptops & Phones at IFA 2026

A Bold Leap by TECNO You walk into the IFA ShowStoppers 2026 event, and what’s greeting you is a flashy splash of next-gen tech from TECNO. Now, if you thought this brand was only about pushing phones, you're in for a ride. TECNO has crashed the laptop party with its new MEGABOOK T15 360 Series, showing it’s more than capable of straddling the tablet and laptop worlds...

AI Platform Suno Sued for Exploiting Artists' Identities

AI and the Music Business: A Legal Storm Brews Well, it looks like the music world’s hitting a rough patch with AI in the crosshairs. We've got Korein Tillery, a heavyweight in the legal arena, throwing down the gauntlet against Suno, an AI music-generation platform. Folks, welcome to the battleground where art meets tech and identity theft takes a whole new meaning....

DELIVAN Unveils Electric Vans and Expansion in Europe

DELIVAN Charging Forward with All-Electric Vans Mark the calendar—September 4, 2026, marked a big day for DELIVAN. The company's foray into the European market is getting serious, splashed across IAA Transportation in all its glory. Unveiling two fresh all-electric production vans, DELIVAN's not just tiptoeing onto the scene; it's diving headfirst into Europe's buzzing...

YSL Beauty’s Block Party Series Rocks London's Scene

YSL Beauty: More Than a Brand, a Cultural Movement London felt a distinct pulse this past weekend as YSL Beauty kicked off another sizzling event in its Block Party series. This one wasn't just another Instagrammable gathering; it was the kind of scene that shifted the cultural needle. What started in Madrid has now become a roving spectacle that sweeps across cities,...

Beko's Innovations in Appliances: Practical Gains Measured

Finding Efficiency in Everyday Routines Let’s kick things off with a no-nonsense look at Beko's thrust into the heart of day-to-day living. This isn’t about bells and whistles, folks—it's about delivering real, quantifiable improvements in how appliances serve us at home. Istanbul's latest reveal is a nod to practicality. From the onset, Beko wraps its hands around...

HoneyNaps Unveils Wireless PSG: Sleep Testing Revolution

Tearing Down the Wired Wall in Sleep Studies Well, here's a switch-up that's long overdue in the world of sleep disorders diagnostics. It looks like HoneyNaps has figured out how to ditch the tangled mess that is traditional polysomnography (PSG) with their new creation—a wireless PSG system, and I gotta say, I'm liking the sound of that. If you've ever been strapped to...